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Uterine adenomyosis was ﬁrst reported in the 19th century and early 20th century; von Rokitansky
described it in 1860. Since then, the general clinical, pathological, and radiologic ﬁndings and
potentially useful management methods have been reviewed in many studies. Some authors com-
mented that conservative surgical treatment is impracticable as it is not possible to isolate the ade-
nomyotic tissue adequately; therefore, the authors suggested that hysterectomy is the only rational
and complete procedure. There is more evidence supporting the advantages of conservative uterine-
sparing surgery in providing not only more effective symptom relief, but also longer durable symptom
control for symptomatic women with uterine adenomyosis, because the main problem secondary to
uterine adenomyosis, dysmenorrhea, can be improved signiﬁcantly, up to 80%. Menorrhea was also
improved in more than two-thirds of patients after type I uterine-sparing surgery, and half of the
patients saw beneﬁt in symptom control after type II conservative uterine-sparing surgery. In addi-
tion, there was no negative impact on reproductive performance after conservative uterine-sparing
surgery, and in fact, reproductive performance seemed to be improved compared with that after
medical treatmentdnot only was there a higher cumulative pregnancy rate, but also a higher cu-
mulative ﬁnal successful delivery rate. However, there is no doubt that the data supporting the above-
mentioned beneﬁts for symptomatic women with uterine adenomyosis after conservative uterine-
sparing surgery are limited, suggesting that the beneﬁt may be moderate. In fact, one of the main
indications for surgery is temporary pain relief in women seeking spontaneous conception. However,
the effect of surgery on pain is usually only temporarily satisfactory, and the risk of complications
varies according to the type of lesion extirpated. In light of this, an extensive review of this topic
addressing conservative surgical treatment for adenomyosis to improve fertility, includingof the Taiwan Association of
hung, Taiwan.
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and might help physicians in managing these patients in the future.
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Karl Freiherr von Rokitansky [1], in 1860, reported the ﬁrst
pathologic description of adenomyosisdsome ﬁbrous tumors in
the uterus that contain gland-like structures that resemble endo-
metrial glands, and the tumors appear to have roots deep within
the uterine muscle layers, so it is hard to distinguish the border of
these tumors within the surrounding myometrial tissues [2]. Ade-
nomyosis is known as “endometriosis (or endometrial glands) of
the myometrium in the uterus”, and these ectopic endometrial
tissues appear to induce hypertrophy and hyperplasia of the sur-
rounding myometriumwith resultant diffusely enlarged uterus [3].
Adenomyosis remains an enigmatic disease and a cause of
abnormal uterine bleeding and dysmenorrhea, subsequently
resulting in chronic pelvic pain and infertility [4]. Adenomyosis-
associated morbidity has a signiﬁcantly negative impact on
women's quality of life, and contributes to long-term major health
issues. Therefore, a better understanding of adenomyosis might
allow less invasive but more accurate diagnostic tests and much
more effective treatment. Although we recently reviewed medical
treatment and uterine-sparing surgery for adenomyosis [5,6], we
wanted to assess whether conservative surgical treatment for
adenomyosis can improve fertility through understanding the
disease inwomen undergoing conservative uterine-sparing surgery
and by discussing the following issues: controversies, indications,
complications, and pregnancy outcome.Controversy
The need for hysterectomy to diagnose adenomyosis means that
it is not easy to diagnose preoperatively. The speciﬁcity of a pre-
operative diagnosis of adenomyosis based on clinical ﬁndings is
poor, ranging from 2% to 26% [7]. The clinical triad of uterine ade-
nomyosis includes abnormal uterine bleeding (nearly 50%), sec-
ondary dysmenorrhea (nearly 30%) and an enlarged, tender uterus
[4]. However, many cases of adenomyosis are asymptomatic, and it
usually affects multiparous women over the age of 40 years [8].
Clinical diagnoses are suspected after an imaging study or after
obtaining an accidental pathological ﬁnding when uterine surgery
is performed for other indications, suggesting that many cases of
adenomyosis go undetected, and this limits our understanding of
the prevalence and clinical impact [7]. There have been several
pathology-based studies published in which women with adeno-
myosis found at hysterectomywere oftenmore parous thanwomen
in which it was not found [9].
There is a lack of consensus in the literature regarding the
relationship between adenomyosis and its associated disease-
related clinical problems, such as fertility. This might have resul-
ted from the retrospective nature of themajority of studies and that
theymainly included populations undergoing hysterectomy [10]. In
addition, these studies used differing criteria for the diagnosis of
adenomyosis, and the majority of them did not quantify the
severity. The results of retrospective studies showed the absence of
a relationship between adenomyosis and the clinical pregnancy
rate. In the adenomyosis group, 99 of 206 women had clinical
pregnancy, contributing to 48.1% of the clinical pregnancy rate [11].Compared with the clinical pregnancy rate of 55.1% (383/695)
among women without adenomyosis, there was no statistically
signiﬁcant difference between the women with and without ade-
nomyosis [risk ratio (RR) 0.84, 95% conﬁdence interval (CI)
0.67e1.06, p ¼ 0.220] [11]. By contrast, prospective studies showed
a signiﬁcant difference in the clinical pregnancy rate between
womenwith and without adenomyosis. Womenwith adenomyosis
had a signiﬁcantly lower clinical pregnancy rate (24/98, 24.5%) than
women without adenomyosis (245/567, 43.2%), with an RR of 0.55
and a 95% CI ranging from 0.32 to 0.96 [11].
In addition, the use of different diagnostic tools also inﬂuenced
the results of the studies. Diagnoses made by ultrasound showed
absence of a relationship between adenomyosis and clinical preg-
nancy rate, but diagnoses made by magnetic resonance imaging
(MRI) showed a strong association between adenomyosis and
clinical pregnancy rate. Of 244 women with ultrasound-diagnosed
adenomyosis, 109 ﬁnally had a clinical pregnancy (44.7%), relatively
similar to the clinical pregnancy rate of 1095 women without
adenomyosis (48.3%); there was no statistically signiﬁcant differ-
ence between the two groups (RR 0.84, 95% CI 0.68e1.04). By
contrast, diagnoses by MRI showed the signiﬁcantly negative
impact of adenomyosis on the clinical pregnancy rate (RR 0.40, 95%
CI 0.25e0.64) [11], suggesting that different study designs
contributed to uncertain and/or inconsistent results. Therefore, the
potential effect of adenomyosis on fertility continues to be debated.
Furthermore, the presence of a concomitant pathology, for
example, leiomyoma (35e55%), endometriosis (6e20%), endome-
trial polyps (2e3%), endometrial hyperplasia with/without atypia
or neoplasms (> 10%), poor ovarian responders (unknown per-
centage), and others, might have a signiﬁcant clinical impact on
diagnoses, symptoms, and results among women with adeno-
myosis [12e19].
Finally, the reproductive outcomes of subfertile women with
adenomyosis seemed to be varied greatly when different protocol
of IVF/ICSI is arranged. Subfertile women with adenomyosis who
were treated with a long-protocol of GnRH agonist in the IVF/ICSI
cycles, women with and without adenomyosis seemed to have the
similar clinical pregnancy rate, with the common RR of clinical
pregnancy per patient of 1.05 (95% CI 0.75e1.48) after pooling data
from two studies [20,21]. By contrast, the clinical pregnancy rate
seemed to be reduced signiﬁcantly when a short protocol was used
in subfertile women with adenomyosis during the IVF/ICSI cycles,
with the RR of 0.58 (95% CI 0.38e0.88) in the summarized data of
four studies [22e25].
All of them are often overlooked in the study of the relationship
between adenomyosis and its clinical observation. Therefore, it is
not easy to explore or study the correlation between adenomyosis
and fertility problems. We would like to conduct an extensive re-
view of this topic, including recent publications, to highlight the
potential inﬂuence of adenomyosis on reproduction.Adenomyosis and fertility
A recent publication by Vercellini et al [11] tried to answer the
following questiondis adenomyosis associated with assisted
reproductive techniques (ART), including in vitro fertilization and
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tematic review and meta-analysis was performed. A summary of
the ﬁndings from Dr. Vercellini et al's [11] study and Dr. Benagiano
et al's [7] article on reproductive outcomes inwomenwith/without
adenomyosis are shown in Table 1. Comparedwith the reproductive
performance of women without adenomyosis, women with ade-
nomyosis seemed to have a lower implantation rate per embryo
transfer, lower clinical pregnancy rate, and lower live birth or
ongoing pregnancy rate, but a higher spontaneous abortion rate.
Womenwith adenomyosis had a signiﬁcant decrease in the clinical
pregnancy rate (RR 0.72, 95% CI 0.55e0.95) and had a twofold risk of
miscarriage (RR 2.12, 95% CI 1.20e3.75), suggesting that the ade-
nomyotic uterine environment increases the risk of miscarriage
independently of oocyte and embryo quality. The overall live birth
rate was signiﬁcantly impaired in women with adenomyosis (RR
0.70, 95% CI 0.56e0.87). Taken altogether, women with adeno-
myosis had a signiﬁcantly decreased clinical pregnancy rate and a
signiﬁcantly increased miscarriage rate, contributing to the signif-
icant decrease in the ﬁnal live birth rate (Table 1), and suggesting
that there is a strong association between adenomyosis and fertility.Indications
Although the above-mentioned evidence seemed to show that
adenomyosis might be associated with a negative impact on
women's fertility, management of thesewomenwith adenomyosis-
associated subfertility is highly controversial, resulting in absence
of consensus of conservative surgery in the management of these
subfertile women with adenomyosis: (1) we do not know who will
beneﬁt from medical treatment alone, such as ART, and who will
beneﬁt from conservative surgery; (2) we do not know when is the
appropriate time for patients to ask for an expert's opinion; and (3)
we do not know whether there will be an improvement in repro-
ductive performance after the use of medical and/or surgical
management.
Before considering the beneﬁts of conservative surgery in the
management of these subfertile women with adenomyosis, we
could not overlook the age factor, because it might be the most
critical factor of fertility. It is well known that fertility declines after
35 years of age, and the chance of miscarriage increases [26].
Unfortunately, uterine adenomyosis is frequently thought to be
a disease of women in their late reproductive age (40e50 years)
and these women often have ﬁnished their childbirth and it is hardTable 1
Summary of clinical pregnancy outcomes in subfertile women with adenomyosis
undergoing ART (IVF/ICSI) treatment.
Parameters Adenomyosis (%) Controls (%)
Implantation rate per ET 18.8e31.0  30












Data are presented as range and cumulative data.
ART ¼ assisted reproductive techniques; ET ¼ embryo transfer; IVF/ICSI ¼ in vitro
fertilization and intracytoplasmic sperm injection.
Note. From “Adenomyosis: a life-cycle approach,” by G. Benagiano, I. Brosens, andM.
Habiba, 2015, Reprod Biomed Online, 30, p. 220e32. Copyright 201X, Name of
Copyright Holder and from “Uterine adenomyosis and in vitro fertilization outcome:
a systematic review and meta-analysis,” by P. Vercellini, D. Consonni, D. Dridi, B.
Bracco, M.P. Frattaruolo, and E. Somigliana, 2014, Hum Reprod, 29, p. 964e77.
Copyright 201X, Name of Copyright Holder. Adapted with permission.
a Data obtained from difference sources contribute to the heterogeneity of the
data presentation.
b Live birth rate includes ongoing pregnancy rate.to convince the physicians that these younger and nulliparous
subfertile women have adenomyosis [27].
A recent study from Japan showed that the clinical pregnancy
rates among women with adenomyosis treated with conservative
surgery were 41.3% in those aged 39 years and 3.7% in those aged
 40 years, suggesting an adverse impact of age on clinical preg-
nancy [odds ratio (OR) 0.77, 95% CI 0.67e0.88, p ¼ 0.002] [14].
Factors associated with clinical pregnancy included history of IVF
treatments (OR 6.22) and posterior wall involvement (OR 0.18).
Therefore, the authors recommended that conservative surgery for
adenomyosis could be a beneﬁcial treatment for women who
experienced IVF treatment failures, especially those aged  39
years [14]. In our previous study assessing factors associated with
future pregnancy and successful delivery in subfertile women with
adenomyosis after combination therapy with conservative surgery
and gonadotropin releasing hormone agonist (GnRH agonist), we
found that age was an important factor associated with future
successful delivery. As a result, we recommended that caution
should be taken in considering themaintenance of future fertility in
older women treated with conservative surgery [17].
In summary, we believe that the clinical evaluation and man-
agement of subfertile womenwith adenomyosis might be similar to
the strategy from other reasons, such as Asherman's syndrome and
endometriosis [28,29]. Our suggestion is shown in Figure 1. The ﬁrst
step is routine infertility workup. Without the use of IVF/ICSI in the
management of women with adenomyosis when these women
have normal ovarian function and normal uterine structure, a long
protocol should be taken into consideration, because these long-
protocol GnRH agonist therapies resulted in a few cases of suc-
cessful pregnancy and live birth [4]. However, it is important to
emphasize that all pregnancies occurred within 12 months after
completing therapy, or immediately to 6 months after the return of
the ﬁrst menstruation when these subfertile women were treated
with a long-protocol GnRH agonist treatment, suggesting that the
pregnancy window is relatively limited and short [9]. Therefore, a
further active management should be switched promptly if preg-
nancy does not occur within the 1st year after completing therapy
or within 6months after the return of menstruation, and this active
management might include repeating the use of a long protocol of
GnRH agonists without ART or a long protocol of GnRH agonist
suppression-based IVF/ICSI should be attempted with all women
[30], if they cannot become pregnant through natural cycles
(Figure 1).
After ART treatment, if patients still fail to become pregnant and
are relatively young ( 39 years of age), conservative surgery might
be an alternative. It is of utmost importance to ensure the deﬁnite
diagnosis of adenomyosis and assess the accurate location and the
size of the adenomyosis focus preoperatively. Complete removal of
focal adenomyosis (adenomyoma) and conservative cytoreductive
surgery of diffuse adenomyosis without marked distortion of the
uterine structure is quite likely to improve the tumor-related
symptoms or morbidity. As it has been reported that ART
methods achieve increased pregnancy rates compared with natural
cycles after conservative surgery for adenomyosis [31], IVF/ISCI
should be arranged for these women after conservative surgical
treatment. In themajority of studies that dealt with pregnancy after
conservative surgery for adenomyosis, attempts at conceptionwere
suggested at least 3 months after the intervention [32,33].
Complications
Before discussing complications after conservative surgery for
adenomyosis, the potential consequences of adenomyosis in terms
of major obstetrical morbidity might needmore research. However,
it is not easy to investigate the relationship between adenomyosis
Figure 1. Algorithm for management of women with adenomyosis-associated infertility. ART ¼ assisted reproductive techniques; GnRH agonist ¼ gonadotropin releasing hormone
agonist; IVF/ICSI ¼ in vitro fertilization and intracytoplasmic sperm injection.
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epidemiology of adenomyosis in pregnancy are available, and
partly because it is uncertain how many pregnancies occur in
women with adenomyosis. In fact, only a few reported
adenomyosis-related complications were found in a literature re-
view. These included rapid growth of adenomyosis or adenomyoma
in pregnancy, spontaneous miscarriage, preterm birth, intrauterine
growth restriction, preeclampsia, obstetric hemorrhages, and
spontaneous rupture of an unscarred uterus during pregnancy or
labor [7,34,35]. In this regard, it has been suggested that alterations
in the inner myometrium of women with adenomyosis may result
in defective remodeling of the spiral arteries during the decidual-
ization process, leading to vascular resistance and an increased risk
of defective deep placentation [11]. However, there is no doubt that
most women with adenomyosis will have an uneventful delivery,
that the inﬂuence of the disease on the course of pregnancy is
unclear, and that it is difﬁcult to provide any useful and speciﬁc
intervention for women with adenomyosis during pregnancy.
Overemphasizing the disease status of adenomyosis with these
womenwho attempt to conceive and/or who are pregnant may not
be necessary.
For those who would like to become pregnant, conservative
surgery might result in additional risk of adhesion, deformity of the
uterus, occlusion of the Fallopian tubes and risk of total and/or
subtotal hysterectomy, similar to any kind of uterine surgery,
including myomectomy [36e39]. In this situation, infertility might
be much more exacerbated, and the ability to get pregnant might
be further compromised. Of course, ART could overcome some of
the above-mentioned sequels.
For the plan of labor, elective cesarean section after conservative
surgery for adenomyosis and/or adenomyomectomy for adeno-
myoma seems a better choice for patient safety [31]. Although a few
case reports showed the possibility of successful vaginal deliveries
in women with adenomyosis after conservative surgery, the ma-
jority of cases were completed by cesarean section. It is recognizedthat uterine ruptures might occur during pregnancy or labor after
conservative surgery for adenomyosis [31]. Furthermore, it is
speculated that subsequent uterine scars may conceal dense re-
sidual adenomyotic foci, and as a consequence, the tensile strength
of the uterus may decline, leading to possible rupture of the
pregnant uterus [38].
Pregnancy outcome
In 2000, we reported three women aged older than 30 years
old with > 60 months of unexplained infertility, who were
treated with a combination of cytoreductive surgery and GnRH
agonist management, and all three had a successful pregnancy
and ﬁnally a term birth by cesarean section [32]. At that time, it
was still hard to convince audiences regarding the value of
conservative surgery in the management of subfertile women
with adenomyosis. However, much more evidence has been ob-
tained to support the potential value of conservative surgery for
adenomyosis.
In a recent review by Grimbizis et al [31], the authors found that
this surgical approach could provide signiﬁcantly improved
symptom control in > 81% (dysmenorrhea control) and 50%
(menorrhagia control) of women with adenomyosis and/or ade-
nomyoma. In addition, pregnancy rates appeared to be > 46% in
women treated with Type II conservative cytoreductive surgery,
and 60% inwomen treatedwith Type I adenomyomectomy surgery;
two-thirds of the women treated with Type II surgery and more
than four-ﬁfths of the women treated with Type I surgery had a
successful delivery (Table 2). Detailed information on Type I and
Type II surgery was introduced in our previous publication [6]. In
brief, in the Type I procedure, complete resection of adenomyosis
(also called adenomyomectomy), all myomectomy procedures can
be applied, with the only difference that the margin between the
tumor and the normal myometrium might not be as clear as with
adenomyomectomy [6]. In the Type II procedure, conservative
Table 2
Summary of pregnancy outcomes in subfertile women with adenomyosis after
different types of conservative surgery treatment.
Surgical methods Type I (n/n, %)a Type II (n/n, %)a
Conception by nature 72/147 (49.0) 15/32 (46.9)
Conception by ART 17/147 (11.6) 0
Total conception 89/147 (60.5) 15/32 (46.9)
Miscarriage 15/89 (16.9) 4/15 (26.7)
Preterm delivery 7/89 (7.9) 0
Term delivery 66/89 (74.2) 10/15 (66.7)
Total delivery 73/89 (82.0) 10/15 (66.7)
ART ¼ assisted reproductive techniques.
Note. From “Adenomyosis: a life-cycle approach,” by G. Benagiano, I. Brosens, andM.
Habiba, 2015, Reprod Biomed Online, 30, p. 220e32. Copyright 201X, Name of
Copyright Holder and from “Endometriosis and infertility: pathophysiology and
management,” by D. de Ziegler, B. Borghese, and C. Chapron. Lancet
2010;376:730e8. Copyright 201X, Name of Copyright Holder. Adapted with
permission.
a Type I and Type II: conservative surgery for adenomyosis and the detailed in-
formation are reported in a previous study [6]. In brief, Type I conservative surgery
involves complete and total excision of adenomyotic foci of the uterus, and Type II
conservative surgery is an attempt to remove all visible adenomyotic foci, which are
widely distributed within the uterus, although this is nearly impossible. The results
of Type II conservative surgery include optimal and suboptimal cytoreduction.
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suboptimal excision of adenomyotic foci in the uterus [6].
In the domestic data, women with localized adenomyosis after
adenomyomectomy treatment had a pregnancy rate that ranged
from 48.2% to 77.5%, and had a successful delivery rate that ranged
from 26.8% to 69.0% [17,33]. Although conservative surgery might
not have a similarly promising effect on reproductive performance
in women with diffuse-type adenomyosis, the pregnancy rate was
> 30e40% in women with extensive adenomyosis after conserva-
tive surgery, amounting to nearly one-fourth to one-third of the
womenwho had a successful delivery [9,32,40]. Comparedwith the
6 months of subfertile women with adenomyosis after medical
treatment with a long protocol GnRH agonist, spontaneous preg-
nancy might occur 36 months after complete conservative surgery,
suggesting that the therapeutic effect of conservative surgerymight
maintain longer than that of medical treatment. Taken together,
conservative surgery might be an alternative if subfertile women
with adenomyosis fail to become pregnant after an active treat-
ment, including a long protocol GnRH agonist treatment and IVF/
ICSI (Figure 1).
Adenomyosis appears to have a detrimental impact on repro-
ductive performance in terms of decreased clinical pregnancy rate
and increased abortion rate; however, many potential confounding
factors could not be adequately assessed. Infertilewomen should be
evaluated for the possibility of adenomyosis, and further discus-
sions and therapeutic plans should be integrated with several other
variables that may have an impact on the likelihood of success [11].
Among these, conservative surgery for symptomatic uterine ade-
nomyosis and its variants appears to be feasible and efﬁcacious,
although data supporting this type of intervention are still subop-
timal [41]. Therefore, the therapeutic strategy might follow the
guideline of infertility evaluation (Figure 1).
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